Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
North American Scientific was a medical technology company that developed and manufactured innovative products for the treatment of cancer, primarily focusing on brachytherapy. The company's core business involved the production of radioactive seeds, such as Prospera (iodine-125) and SurTRAK (palladium-103), used in the treatment of prostate cancer. Additionally, the company developed the ClearPath system, a multi-lumen breast brachytherapy device designed to provide more precise radiation delivery. Through its subsidiary, Theseus Imaging Corporation, the company also advanced a pipeline of radiopharmaceuticals, most notably Apomate, an imaging agent for detecting apoptosis in cardiovascular and oncological conditions. Despite its established product lines, North American Scientific faced significant financial challenges and filed for Chapter 11 bankruptcy in 2009. Its assets were subsequently acquired by Best Medical International, which integrated the technologies into its own radiation therapy portfolio.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on North American Scientific.